Luo Xiaoqin, Li Jiang, Chen Sisi, Luo Jun
Department of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Front Pharmacol. 2022 Oct 17;13:992457. doi: 10.3389/fphar.2022.992457. eCollection 2022.
Drug-induced pulmonary arterial hypertension (PAH) has been widely reported but PAH caused by leflunomide is very rare. Here we report the case of a young man with nephrotic syndrome treated with leflunomide for 5 years before being admitted to our hospital for dyspnea. After discontinuing leflunomide treatment for 4 months, both the dyspnea and pulmonary artery systolic pressure improved. Right heart catheterization showed in a significant decrease in pulmonary vascular resistance and pulmonary artery pressure 4 months later. Because persistent PAH can lead to right heart failure and even death, identifying and excluding the risk factors is critical; discontinuing leflunomide until a definite cause is identified is highly recommended.
药物性肺动脉高压（PAH）已有广泛报道，但来氟米特引起的PAH非常罕见。在此，我们报告一例年轻男性肾病综合征患者，他接受来氟米特治疗5年后因呼吸困难入院。在停用4个月来氟米特治疗后，呼吸困难和肺动脉收缩压均有所改善。右心导管检查显示4个月后肺血管阻力和肺动脉压力显著降低。由于持续性PAH可导致右心衰竭甚至死亡，识别和排除危险因素至关重要；强烈建议在确定明确病因之前停用 来氟米特。
